RESEARCH PIPELINE

FNDR has generated a pipeline of therapeutics in various bacterial, viral, fungal and parasitic indications spanning over early-stage discovery to late-stage clinical trials. 

Hit to Lead
Lead Optimization
IND Enabling Studies
Repurposed Drugs
Phase 1
Phase 2
Phase 3

TUBERCULOSIS

NONTUBERCULOUS MYCOBACTERIA

BACTERIAL INFECTIONS

FUNGAL INFECTIONS

MALARIA

LEISHMANIA

COVID-19

RESPIRATORY SYNCYTIAL VIRUS

DENGUE

PROJECT DETAILS

 
 

TBA-7371

Tuberculosis

Clinical, Phase 2

A DprE1 inhibitor being developed for tuberculosis. The patent is jointly held by TB Alliance and FNDR. Phase 2 Clinical trial is being carried out by Gates Medical Research Institute in South Africa (Trial No. NCT04176250)

FNDR20364

Tuberculosis, NTM, Bacterial Infections

Preclinical, IND Enabling Studies

A novel anti-TB compound extracted from the soil of Antarctica, has shown promising activity against drug resistant TB. FNDR is a patent holder along with National Centre for Polar and Ocean Research, Ministry of Earth Sciences, Government of India. Development for TB is funded by BIRAC. It is also known as NF1001. FNDR20364 has also shown excellent in vitro activity against multiple drug sensitive and drug resistant NTMs and its development for NTMs is funded by the Cystic Fibrosis Foundation (CFF), USA. FNDR20364 also works against drug resistant Gram-postive bacteria.

FNDR10045

Tuberculosis

Preclinical, Lead Optimization

A potent DprE1 inhibitor for the treatment of Tuberculosis. It has completed lead optimization.

FNDR11131

Tuberculosis

Preclinical, Lead Optimization

A multi-targeting pre-clinical candidate against drug-resistant tuberculosis. Currently under lead optimization phase.

Chloroquine

Tuberculosis

Preclinical, Repurposed Drug

A well-known clinical candidate repositioned for shortening TB therapy in partnership with Indian Institute of Science (IISc), Bangalore. The project is funded by DBT India.

Saracatinib

Tuberculosis

Repurposed Drug, Preclinical

Saracatinib is a kinase inhibitor that is being explored as a host-immunomodulatory drug to shorten the treatment duration of drug sensitive and drug resistant TB. The project is in collaboration with ICGEB New Delhi and is funded by BIRAC.

Novel Series (Tuberculosis)

Tuberculosis

Preclinical, Hit to Lead

A series of compounds with a novel cell wall target which has shown promising anti-TB efficacy. The project is funded by DBT India.

Novel Series (Tuberculosis)

Tuberculosis

Hit to Lead, Preclinical

A series of compounds with a novel chemical scaffold that have shown promising anti-TB efficacy. Currently in early preclinical stage.

Novel Series (NTMs)

NTM

Hit to Lead, Preclinical

A series of compounds with a novel chemical scaffold that have shown promising efficacy against multiple NTM strains. Currently in early preclinical stage.

Novel Series (Bacterial Infections)

Bacterial Infections

Preclinical, Hit to Lead

FNDR, ABAC Therapeutics Spain and Peptris Technologies have partnered to work on a first in class broad spectrum antibiotic working against Gram negative bacteria.

Novel Series (Bacterial Infections)

Bacterial Infections

Hit to Lead, Preclinical

FNDR has partnered with Oppilotech UK to discover and develop small molecule antibiotics that work on WHO priority pathogens through a novel mechanism. The project is in early preclinical stage.

Amphotericin B (Oral formulation)

Fungal Infections, Leishmania

Repurposed Drug, Preclinical

Liposomal Amphotericin B is an injectable drug for fungal infections and leishmania. FNDR has partnered with AIIMS New Delhi to develop an oral formulation of Amphotericin B and the project is funded by DBT India.

 
 
 
 
 
 
 
 
 
 

FNDR20123

Malaria

Preclinical, IND Enabling Studies

A novel compound with new mechanism which has shown excellent activity against various malarial strains. IND enabling studies are being planned.

Novel Series (Malaria)

Malaria

Preclinical, Hit to Lead

A compound series with a novel mechanism, which has shown excellent activity against various malarial strains. It is currently under Hit to Lead stage.

FNDR30060

Leishmania

Preclinical, IND Enabling Studies

A novel immunomodulator which potentiates the action of existing drugs against Leishmaniasis.

FNDR11167

COVID-19, hRSV

Preclinical, Lead Optimization

A novel compound series with broad spectrum antiviral activities. It has shown excellent in vitro and in vivo efficacy against SARS-CoV-2 and RSV.

FNDRC1002

COVID-19

Preclinical, Repurposed Drug

A repurposed drug with well established safety profile has shown excellent in vitro and in vivo efficacy against SARS-CoV-2

Novel Series (Dengue)

Dengue

Preclinical, Hit to Lead

A novel class of compounds which works on all 4 serotypes of Dengue virus. It is currently under Hit to lead stage and jointly being developed with National University of Singapore.

Device for Antibiotic Depletion from Industrial Waste Water/Hospital Effluents

AMR

Validation

FNDR is developing a novel device made of waste materials to remove antibiotics from waste water. Antimicrobial resistance (AMR) is a global threat due to discharge/dumping of antibiotics from industries such as API manufacturing, poultry, fisheries, animal husbandry, and hospitals. Currently there is no device to deplete antibiotics from effluents. The lab scale device is ready and prototype device in development.

Biomarkers To Detect Tuberculosis

Tuberculosis

Proof of Concept

FNDR is developing a blood-based diagnostic for rapid detection of pulmonary and extra-pulmonary tuberculosis. Current biomarker-based tests for Pulmonary TB are low in accuracy or specificity. No tests exist for Extra-pulmonary TB. Clinical trial of 200 patients at St John’s Hospital, Bangalore has been completed to test for biomarkers in blood and urine. Data is promising and indicates potential for a rapid biomarker (blood) based diagnostic which can be converted to a Point of Care Test.

Biomarkers To Differentiate Bacterial Vs Viral Infections

AMR

Proof of Concept

FNDR is developing a blood-based diagnostic for rapid differentiation between bacterial and viral infections to guide antibiotic prescriptions . Antimicrobial resistance (AMR) is a global threat due to misuse of antibiotics. Currently there is no biomarker test on market. Pre-clinical validation has been completed and clinical trial to establish clinical validation is in progress.